Cariprazine-induced mania: A case series report

dc.contributor.authorPons-Cabrera, Maria Teresa
dc.contributor.authorPalacios-Garran, Roberto
dc.contributor.authorTardón, Laia
dc.contributor.authorFernández Plaza, Tábatha
dc.contributor.authorMarco-Estrada, Oriol
dc.contributor.authorMadero Gómez, Santiago
dc.contributor.authorAnmella, Gerard
dc.contributor.authorColomer, Lluc
dc.contributor.authorDruetta, Mauro
dc.contributor.authorGiménez Palomo, Anna
dc.contributor.authorNavarro-Cortés, L.
dc.contributor.authorSagué Vilavella, Maria
dc.contributor.authorSánchez-Sierra, Carlos
dc.contributor.authorVerdolini, Norma
dc.contributor.authorCatalán Campos, Rosa
dc.contributor.authorBioque Alcázar, Miquel
dc.contributor.authorGoikolea, José Manuel
dc.contributor.authorVieta i Pascual, Eduard, 1963-
dc.contributor.authorPacchiarotti, Isabella
dc.date.accessioned2026-06-30T12:19:13Z
dc.date.available2026-06-30T12:19:13Z
dc.date.issued2021-11-19
dc.date.updated2026-06-30T12:19:13Z
dc.description.abstractBipolar depression is the most prevalent phase of bipolar disorder (BD). There is a risk of inducing treatment-emergent affective switches (TEAS) with antidepressants (ADs). Hence, clinical guidelines do not recommend their use in monotherapy. Cariprazine is a dopamine-serotonin partial agonist, with a recent FDA approval as a monotherapy for BD type 1 (BD-I) depression. To our knowledge, there is no significant evidence of cariprazine-induced TEAS in bipolar depression. We describe three clinical cases of patients admitted to our acute psychiatric ward who developed manic episodes after the introduction of low doses of cariprazine. Two of the patients met the DSM-5 criteria for BD-I, and one for schizoaffective disorder, bipolar type. All patients were initially treated with low doses of cariprazine (1.5 mg) during a depressive phase. All three cases were simultaneously treated with mood stabilizers, regardless of which they switched to a manic episode when cariprazine was initiated. In our review of previous studies assessing the efficacy and side effects profile of cariprazine in BD-I, TEAS have not been found to be significant. However, according to our experience, cariprazine may induce affective switches in BD-I patients. Patients and psychiatrists should receive information regarding early warning symptoms and monitor possible cariprazine-induced mood switching.
dc.format.extent4 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec716511
dc.identifier.issn1398-5647
dc.identifier.pmid34797609
dc.identifier.urihttps://hdl.handle.net/2445/230298
dc.language.isoeng
dc.publisherJohn Wiley & Sons
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1111/bdi.13156
dc.relation.ispartofBipolar Disorders, 2021, vol. 24, num.4, p. 457-460
dc.relation.urihttps://doi.org/10.1111/bdi.13156
dc.rightscc-by (c) Pons-Cabrera, Maria Teresa et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationTrastorn bipolar
dc.subject.classificationAntidepressius
dc.subject.classificationTrastorns afectius
dc.subject.otherManic-depressive illness
dc.subject.otherAntidepressants
dc.subject.otherAffective disorders
dc.titleCariprazine-induced mania: A case series report
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
243760.pdf
Mida:
287.67 KB
Format:
Adobe Portable Document Format